Maze Therapeutics (MAZE) Other Non-Current Liabilities (2024 - 2026)

Maze Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $388000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 61.43% year-over-year to $388000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $388000.0 (down 61.43% YoY) and the FY2025 annual result came in at $1.1 million, up 12.9% from the prior year.
• Other Non-Current Liabilities declined to $388000.0 in Q1 2026 per MAZE's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $1.1 million in Q4 2025 and troughed at $388000.0 in Q1 2026.
• A 3-year average of $939666.7 and a median of $1.0 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities climbed 12.9% in 2025, then sank 61.43% in 2026.
• Over 3 years, Other Non-Current Liabilities stood at $969000.0 in 2024, then gained by 12.9% to $1.1 million in 2025, then plunged by 64.53% to $388000.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $388000.0, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.